AVTX
Avalo Therapeutics, Inc.
Key Financials
Revenue
$59000
↓ 86.6%
Net Income
$-78259000
↓ 122.8%
Operating Income
$-72925000
↓ 6.4%
EPS (Diluted)
$-5.84
↑ 72.1%
Total Assets
$116.5M
↓ 22.7%
Shareholders' Equity
$83.0M
↓ 37.6%
Total Liabilities
$33.4M
↑ 88.8%
Cash & Equivalents
$15.9M
↓ 88.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 6/25/2026 | View on SEC |
| 4 | 6/25/2026 | View on SEC |
| 3 | 6/25/2026 | View on SEC |
| 8-K | 6/23/2026 | View on SEC |
| SCHEDULE 13G | 6/18/2026 | View on SEC |
| 8-K | 6/16/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AVTX |
| Company Name | Avalo Therapeutics, Inc. |
| CIK | 1534120 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 410-522-8707 |